<DOC>
	<DOCNO>NCT02859038</DOCNO>
	<brief_summary>The purpose study answer fundamental question , physician choose Surgery Chemotherapy ( SOC 2 ) advance ovarian cancer ?</brief_summary>
	<brief_title>Study Upfront Surgery Versus Neoadjuvant Chemotherapy Patients With Advanced Ovarian Cancer ( SUNNY )</brief_title>
	<detailed_description>OBJECTIVES : Compare efficacy safety patient FIGO ( 2014 ) stage IIIC IV epithelial ovarian cancer , fallopian tube cancer , peritoneal carcinoma treat neoadjuvant chemotherapy follow interval debulking surgery versus upfront surgery . OUTLINE : This randomized phase III multicenter study . Patients receive upfront maximal cytoreductive surgery follow least 6 cycle adjuvant chemotherapy 3 cycle neoadjuvant chemotherapy follow interval debulking surgery , least 3 cycle adjuvant chemotherapy . Patients follow every 3 month within first 5 year , every 6 month . PROJECTED ACCRUAL : A total 456 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>1 . Women age ≥ 18 year . 2 . Pathologic confirm stage IIIC IV epithelial ovarian cancer , fallopian tube cancer primary peritoneal carcinoma ( diagnosis biopsy fine needle aspiration* ) . Laparoscopic biopsy picture recommend . * If fine needle aspiration show adenocarcinoma , patient satisfy follow condition : a. patient pelvic mass , b. omental cake metastasis large 2 cm upper abdomen , pathologic confirm extraabdominal metastasis , c. serum CA125/CEA ratio &gt; 25 . If serum CA125/CEA ratio &lt; 25 malignancy origin , breast digestive tract , suspect symptom , physical examination image diagnosis , endoscopy ultrasonography do exclusive metastasis ovarian cancer . 3 . ECOG performance status 0 2 . 4 . ASA score 1 2 . 5 . Adequate bone marrow , liver renal function receive chemotherapy subsequently undergo surgery : 1. white blood cell &gt; 3,000/µL , absolute neutrophil count ≥1,500/µL , platelets ≥100,000/µL , hemoglobin ≥9 g/dL , 2. serum creatinine &lt; 1.25 x upper normal limit ( UNL ) creatinine clearance ≥60 mL/min accord CockroftGault formula local lab measurement , 3. serum bilirubin &lt; 1.25 x UNL , AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x UNL . 6 . Comply study protocol followup . 7 . Written informed consent . 1 . Patients nonepithelial tumor well borderline tumor . 2 . Mucinous ovarian cancer . 3 . Low grade ovarian cancer . 4 . Synchronous metachronous ( within 5 year ) malignancy carcinoma situ . 5 . Any concurrent medical condition contraindicate surgery chemotherapy could compromise adherence protocol . 6 . Other condition , religious , psychological factor , could interfere provision inform consent , compliance study procedure , followup .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>